Early increase of soluble urokinase plasminogen activator receptor (suPAR) serum levels is
indicative of increased risk of progression of coronavirus disease 2019 (COVID-19) to …

Background At the end of 2021, the European Medicines Agency (EMA) expanded its
approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the …

Background: It was studied if early suPAR-guided anakinra treatment can prevent severe
respiratory failure (SRF) of COVID-19. Methods: A total of 130 patients with suPAR≥ 6 ng/ml …

Around the tenth day after diagnosis,∼ 20% of patients with coronavirus disease 2019
(COVID-19)− associated pneumonia evolve toward severe oxygen dependence (stage 2b) …

Background Anakinra might improve the prognosis of patients with moderate to severe
COVID-19 (ie, patients requiring oxygen supplementation but not yet receiving organ …

Background Patients with COVID-19 pneumonia have an excess of inflammation and
increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine …

Background: Efficient healthcare based on prognostic variables in hospitalised patients with
COVID-19 could reduce the risk of complications and death. Recently, soluble urokinase …

Background Coronaviruses can induce the production of interleukin (IL)-1β, IL-6, tumour
necrosis factor, and other cytokines implicated in autoinflammatory disorders. It has been …

Background Mortality of patients with coronavirus disease 2019 (COVID-19), acute
respiratory distress syndrome (ARDS), and systemic inflammation is high. In areas of …

Introduction Severe COVID-19 cases have a detrimental hyper-inflammatory host response
and different cytokine-blocking biologic agents were explored to improve outcomes …